<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368729</url>
  </required_header>
  <id_info>
    <org_study_id>F2017000 (UAB 17112)</org_study_id>
    <nct_id>NCT03368729</nct_id>
  </id_info>
  <brief_title>Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer</brief_title>
  <official_title>A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Breast Cancer Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Susan G. Komen Breast Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Breast Cancer Research Foundation of Alabama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VFoundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The human epidermal growth factor receptor 2 (HER2) regulates cell growth and survival.&#xD;
      Approximately 15-20% of all breast cancers are HER2-positive, which are an aggressive and&#xD;
      fast-growing subtype of breast cancer. This study will evaluate a new treatment using a&#xD;
      potent Poly polymerase (PARP) inhibitor known as Niraparib. Niraparib will be combined with&#xD;
      trastuzumab, a HER2-targeted agent, to evaluate the safety and tolerability in patients with&#xD;
      metastatic HER2 positive breast cancer. It is anticipated that the combination of drugs will&#xD;
      improve survival and have few side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment will be administered on an outpatient basis. All patients in the phase 1 and 2&#xD;
      portion of the study will receive Niraparib by mouth on days 1-21 of each 21 day cycle as&#xD;
      well as trastuzumab intravenously (IV) on day 1 of each cycle. Blood and tissue will be&#xD;
      collected at pre-specified times to enable pharmacokinetic, biomarker, and toxicity studies.&#xD;
      The drug dosage will then be determined for the phase 2 portion at a dose limiting level.&#xD;
      Following treatment, patients will be followed every 6 weeks for 6 months until disease&#xD;
      progression or an unacceptable adverse event.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>There are two phases to this study. Phase 1 will enroll 6-12 patients and Phase 2 will enroll up to 40. Trastuzumab will be given intravenously at 6 mg/kg on Day 1 for each 21 day cycle in both phases. Niraparib will be given by mouth every day at a dosage of 200 mg for phase 1 participants and 200 mg (or 100 mg) for phase 2 participants. Tumor measurement and response will be monitored by MRI or CT scans after cycles 3 and 6 and then every 12 weeks for up to 2 years or until disease progression. Blood and tissue samples will be collected for pharmacokinetics, biomarkers, and laboratory evaluations.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Dose-limiting toxicity (DLT)</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>A DLT is defined as hematological events &gt; or equal to grade 3 leukopenia, anemia, and thrombocytopenia and also non-hematological events &gt; or equal to grade 3 fatigue, nausea, constipation, vomiting, or diarrhea.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Objective Response Rate</measure>
    <time_frame>Baseline up to 100 weeks</time_frame>
    <description>Response and progression of disease will be evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Baseline up to 100 weeks</time_frame>
    <description>Toxicities will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Baseline to the date of first documented progression to date of death from any cause, whichever comes first, assessed up to 100 months</time_frame>
    <description>The RECIST v. 1.1 criteria will be used to evaluate progression-free survival as well as CT and MRI scans. Progression is indicative of existing target and non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Niraparib levels</measure>
    <time_frame>Baseline to 25 days</time_frame>
    <description>Plasma niraparib levels will be assessed at specific time points in participants blood during cycle 2 treatment in Phase I patients only. A population pharmacokinetic modeling approach will be used to describe area under the curve (AUC) plasma concentrations of niraparib and its metabolites in participants in this study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>HER2 Positive Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Phase 1: Niraparib 200 mg + Trastuzumab 6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In phase 1 patients in this first arm will receive 200 mg Niraparib in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Niraparib 100 mg + Trastuzumab 6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In phase 1 patients in this second arm will receive Niraparib 100 mg in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Niraparib 200 mg or 100 mg + Trastuzumab 6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dosage of Niraparib in phase 2 will be determined by the response of patients in Phase 1. A dosage of Niraparib 200 mg will be given along with Trastuzumab 6 mg/kg IV unless a dose limiting toxicity occurs in Phase 1. If so, Niraparib 100 mg will be given with Trastuzumab 6 mg/kg (instead of Niraparib 200 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib</intervention_name>
    <description>Niraparib is an oral PARP-1 and -2 inhibitor with high potency.</description>
    <arm_group_label>Phase 1: Niraparib 100 mg + Trastuzumab 6 mg/kg</arm_group_label>
    <arm_group_label>Phase 1: Niraparib 200 mg + Trastuzumab 6 mg/kg</arm_group_label>
    <arm_group_label>Phase 2: Niraparib 200 mg or 100 mg + Trastuzumab 6 mg/kg</arm_group_label>
    <other_name>formerly MK-4827</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab is a commercially available agent administered by intravenous infusion. A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.</description>
    <arm_group_label>Phase 1: Niraparib 100 mg + Trastuzumab 6 mg/kg</arm_group_label>
    <arm_group_label>Phase 1: Niraparib 200 mg + Trastuzumab 6 mg/kg</arm_group_label>
    <arm_group_label>Phase 2: Niraparib 200 mg or 100 mg + Trastuzumab 6 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women age ≥ 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0-2 (Karnofsky &gt;60%).&#xD;
&#xD;
          -  Patients with metastatic breast cancer.&#xD;
&#xD;
          -  HER2 (human epidermal growth factor receptor 2)-positive breast cancer prospectively&#xD;
             determined on the primary tumor by a local pathology laboratory and defined as:&#xD;
             Immunohistochemistry (IHC) score of 3+ and/or positive by ISH (defined by In Situ&#xD;
             Hybridization ratio of ≥ 2.0 for the number of HER2 gene copies to the number of&#xD;
             chromosome 17 copies). Both IHC and ISH assays will be performed; however, only one&#xD;
             positive result is required for eligibility.&#xD;
&#xD;
          -  Estrogen/progesterone receptor positive OR negative disease allowed.&#xD;
&#xD;
          -  Patients must have measurable disease per the Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) v1.1.&#xD;
&#xD;
          -  Patients that have failed at least one anti-HER2 therapy in the metastatic setting.&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  absolute neutrophil count ≥1,500/mL&#xD;
&#xD;
               -  platelets ≥100,000/mL&#xD;
&#xD;
               -  total bilirubin ≤ institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  aspartate aminotransferase (AST)/alanine aminotransferase (ALT) 5 ≤ X&#xD;
                  institutional ULN&#xD;
&#xD;
               -  creatinine ≤ institutional ULN OR creatinine clearance ≥ 60 mL/min/1.73 m2 for&#xD;
                  patients with creatinine levels above institutional normal.&#xD;
&#xD;
          -  Baseline left ventricular ejection fraction (LVEF) ≥ 50% measured by echocardiogram&#xD;
             (preferred) or multigated acquisition (MUGA) scans.&#xD;
&#xD;
          -  Willing and able to comply with the requirements of the protocol.&#xD;
&#xD;
          -  Patient is able to take oral medication.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Female patients of childbearing potential must be willing to use one highly effective&#xD;
             form of hormonal contraception or two effective forms of nonhormonal contraception.&#xD;
&#xD;
          -  Contraception must continue for the duration of study treatment and for 7 months after&#xD;
             the last dose of study treatment. The above contraception is not a requirement in the&#xD;
             case of any of the following:&#xD;
&#xD;
               -  The patient, or partner of the patient, is surgically sterilized.&#xD;
&#xD;
               -  The female patient is &gt;45 years of age and is postmenopausal (has not menstruated&#xD;
                  for at least 12 consecutive months&#xD;
&#xD;
               -  The patient truly abstains from sexual activity and when this is the preferred&#xD;
                  option to avoid conception and contraception and/or usual lifestyle of the&#xD;
                  patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic breast cancer patients who are HER2 positive and have NOT progressed on at&#xD;
             least one prior HER2-targeted therapies for metastatic disease&#xD;
&#xD;
          -  Patients who have not recovered from CTCAE, v. 4.03 grade 2 or higher toxicities of&#xD;
             prior therapy to the point that they would be appropriate for re-dosing will be&#xD;
             ineligible for study treatment. Subjects receiving weekly therapy must have a washout&#xD;
             period from prior chemotherapy of as least one week. Washout period for chemotherapy&#xD;
             administered every 2, 3, or 4 weeks will be 2, 3, and 4 weeks respectively, provided&#xD;
             subject has recovered from toxicities of prior therapy such that retreatment is&#xD;
             appropriate.&#xD;
&#xD;
          -  Patients must be at least two weeks from prior RT&#xD;
&#xD;
          -  Patients must have a one-week washout period from prior hormonal therapy (e.g.&#xD;
             testosterone, estrogen, progestin, gonadotropin-releasing hormone antagonist).&#xD;
&#xD;
          -  Patient has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
        Note: Patients with previously treated brain metastases may participate provided they are&#xD;
        stable (without evidence of progression by imaging [using the identical imaging modality&#xD;
        for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of&#xD;
        study treatment and any neurologic symptoms have returned to baseline), have no evidence of&#xD;
        new or enlarging brain metastases, and have not been using steroids for at least 7 days&#xD;
        prior to study treatment. Carcinomatous meningitis precludes a patient from study&#xD;
        participation regardless of clinical stability.&#xD;
&#xD;
        No concurrent anti-cancer treatment of any type&#xD;
&#xD;
          -  Patients with known germline BRCA 1 or BRCA 2 mutations&#xD;
&#xD;
          -  Patient has undergone prior treatment with a known poly(ADP-ribose) polymerase (PARP)&#xD;
             inhibitor.&#xD;
&#xD;
          -  Prior treatment of a total doxorubicin &gt;360 mg/m2 (or equivalent)&#xD;
&#xD;
          -  Patient has known active hepatitis B (eg, hepatitis B surface antigen [HBsAg]&#xD;
             reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid [HCV RNA]&#xD;
             [qualitative] is detected).&#xD;
&#xD;
          -  Patient has a known history of human immunodeficiency virus (HIV) (HIV 1/2&#xD;
             antibodies).&#xD;
&#xD;
          -  Chronic immunosuppressive therapies including systemic corticosteroids or concurrent&#xD;
             short-term use of immunosuppressive therapies is not allowed. Short- term&#xD;
             corticosteroid use must be discontinued at least 2 weeks prior to study treatment.&#xD;
&#xD;
          -  Patients with known grade 2 or greater allergic reactions attributed to compounds of&#xD;
             similar chemical or biological composition to niraparib are ineligible for study&#xD;
             enrollment.&#xD;
&#xD;
          -  Patients with known grade 2 or greater allergic reactions attributed to compounds of&#xD;
             similar chemical or biological composition to herceptin are ineligible for study&#xD;
             enrollment.&#xD;
&#xD;
          -  Patient is pregnant or breastfeeding, or expecting to conceive children within the&#xD;
             projected duration of the study, starting with the screening visit through 7 months&#xD;
             after the last dose of study treatment.&#xD;
&#xD;
          -  History of non-breast malignancies within the 5 years prior to study entry, except for&#xD;
             the following:&#xD;
&#xD;
               -  Carcinoma in situ (CIS) of the cervix&#xD;
&#xD;
               -  CIS of the colon&#xD;
&#xD;
               -  Melanoma in situ&#xD;
&#xD;
               -  Basal cell and squamous cell carcinomas of the skin&#xD;
&#xD;
          -  Patient is considered a poor medical risk due to a serious, uncontrolled medical&#xD;
             disorder, nonmalignant systemic disease or active infection that requires systemic&#xD;
             therapy. Specific examples include, but are not limited to, active, non-infectious&#xD;
             pneumonitis; uncontrolled major seizure disorder; unstable spinal cord compression;&#xD;
             superior vena cava syndrome; or any psychiatric or substance abuse disorders that&#xD;
             would interfere with cooperation with the requirements of the study (including&#xD;
             obtaining informed consent).&#xD;
&#xD;
          -  Cardiopulmonary dysfunction as defined by any of the following prior to randomization:&#xD;
&#xD;
               -  History of National Cancer Institute Common Terminology Criteria for Adverse&#xD;
                  Events (NCI CTCAE; Version 4.0) Grade ≥3 symptomatic congestive heart failure&#xD;
                  (CHF) or New York Heart Association (NYHA) criteria Class ≥ II&#xD;
&#xD;
               -  Angina pectoris requiring anti-angina medication, serious cardiac arrhythmia not&#xD;
                  controlled by adequate medication, severe conduction abnormality, or clinically&#xD;
                  significant valvular disease&#xD;
&#xD;
               -  High-risk uncontrolled arrhythmias (i.e. atrial tachycardia with a heart rate&#xD;
                  &gt;100/min at rest, significant ventricular arrhythmia [ventricular tachycardia],&#xD;
                  or higher-grade atrioventricular [AV]-block [second degree AV-block Type 2&#xD;
                  [Mobitz 2] or third degree AV-block])&#xD;
&#xD;
               -  Significant symptoms (Grade ≥2) relating to left ventricular dysfunction, cardiac&#xD;
                  arrhythmia, or cardiac ischemia&#xD;
&#xD;
               -  Myocardial infarction within 12 months prior to randomization&#xD;
&#xD;
               -  Uncontrolled hypertension (systolic blood pressure &gt;180 mmHg and/or diastolic&#xD;
                  blood pressure &gt;100 mmHg)&#xD;
&#xD;
               -  Evidence of transmural infarction on ECG&#xD;
&#xD;
               -  Heart-rate corrected QT interval (QTc) prolongation &gt;470 msec at screening.&#xD;
&#xD;
               -  Requirement for oxygen therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This study is for women only.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erica Stringer-Reasor, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erica Stringer-Reasor, M.D.</last_name>
    <phone>205-975-2816</phone>
    <email>strinem@uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eddy Yang, M.D., Ph.D.</last_name>
    <phone>205-934-2762</phone>
    <email>eyang@uab.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Stringer-Reasor, M.D.</last_name>
      <phone>205-975-2816</phone>
      <email>strinem@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Hardwick</last_name>
      <phone>205-975-5387</phone>
      <email>pamdixon@uab.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Nanda, MD</last_name>
      <phone>773-834-7756</phone>
      <email>rnanda@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chloe Kuhn</last_name>
      <phone>773-702-1220</phone>
      <email>ckuhn1@medicine.bsd.uchicago.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rita Nanda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minetta Liu, MD</last_name>
      <email>Liu.Minetta@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Adrienne Benson</last_name>
      <phone>507-284-3045</phone>
      <email>benson.adrienne@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Minetta Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Anampa, MD</last_name>
      <phone>718-405-8404</phone>
      <email>JANAMPA@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Ana Maria Guarin</last_name>
      <phone>718-405-8428</phone>
      <email>abernal@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jesus Anampa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Dees, MD</last_name>
      <phone>919-842-7714</phone>
      <email>Claire_dees@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Pfeffer, RN BSN</last_name>
      <email>tamara_pfeffer@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Claire Dees, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Clark, MD</last_name>
      <email>Amy.Clark@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Noah Goodman, MPH</last_name>
      <phone>215-260-8518</phone>
      <email>noah.goodman@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Amy Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington-</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Specht, MD</last_name>
      <phone>206-606-2053</phone>
      <email>jspecht@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sya Magee</last_name>
      <phone>(206) 606-6424</phone>
      <email>smagee@seattlecca.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer Specht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Erica Stringer-Reasor</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>Poly (ADP-Ribose) polymerase (PARP)</keyword>
  <keyword>Niraparib</keyword>
  <keyword>Trastuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

